EGFR and medulloblastoma: Sahm et al. [12] found that information derived from their NGS protocol identified potential targets for experimental therapy (i.e. EGFR, BRAF, PTEN in 37/47 (79%) glioblastomas, 9/10 (90%) pilocytic astrocytomas, and 5/14 (36%) medulloblastomas in a prospective cohort (n = 71) [22].